The Biologics CMC Development organization at AbbVie has a long and rich history of biologics development, leveraging comprehensive end-to-end CMC capabilities to advance complex biologic therapies, such as bi-specifics and novel modalities, from discovery through human clinical studies and eventual licensure. Apply a rigorous theoretical and practical understanding of recombinant protein expression from the genome to the protein — including genomic loci, epigenetics, transcription, mRNA stability, translation, the organelles and secretory machinery involved, and the engineering constraints specific to industrial CHO cell line development.